Akura Medical Secures $53 Million in Series C Funding to Revolutionize Venous Thromboembolism Care

Akura Medical Secures $53 Million in Series C Funding

Akura Medical, a portfolio company of Shifamed, has made a significant stride in advancing the field of venous thromboembolism (TEV) care by securing a Series C funding of $53 million. The funding will primarily support the development of the innovative Katana™ thrombectomy system and the NavIQ™ quantification software, which are pivotal in elevating patient outcomes and procedural accuracy in the treatment of TEV.

On December 1, 2025, Akura Medical officially announced the closure of this funding round, which was led by the Qatar Investment Authority (QIA), with participation from existing investors. A portion of this capital will also be utilized to establish a joint venture in Qatar, enhancing their international reach and operational capabilities.

Focus on Innovative Technologies

Amr Salahieh, the interim CEO of Akura Medical, expressed his enthusiasm about the funding, stating, "Akura Medical is driving a differentiated portfolio of venous thrombectomy technologies aimed at improving procedural precision and patient outcomes. The recent introduction of our NavIQ quantification software represents the next step toward data-driven thrombectomy. This new capital allows us to expedite product development and continue laying the groundwork for long-term growth. We are grateful for QIA's trust and collaboration in bringing our vision to reality."

The Akura Medical product line includes both the flagship Katana system and the upcoming NavIQ software. The Katana system is designed with advanced technology to remove various types of clots effectively. It optimizes catheter placement and provides in-depth intraoperative feedback, which is crucial for surgical success. The system employs high-speed saline jets designed to dissolve clots regardless of their morphology while preventing catheter blockage, thus enhancing procedural efficiency. Moreover, it is equipped with sensors that offer real-time pulmonary artery pressure data, significantly aiding procedural navigation.

In parallel, NavIQ serves as a cutting-edge software solution that transforms CT angiography images into a 3D model of the pulmonary vasculature. This innovative approach offers anatomical visualization of arteries and clots, thereby enhancing preoperative planning. Additionally, it provides clot characterization data, enabling doctors to prioritize treatment based on specific clinical needs.

The Impact of TEV

TEV stands as the third leading cause of cardiovascular death in the U.S., often resulting from clots forming in deep veins of the legs, which can severely inhibit or block blood flow to the lungs. Akura Medical aims to change this narrative by providing advanced solutions that make a considerable difference in patient care and recovery.

Akura Medical, Inc., based in Los Gatos, California, is a private sector innovation leader focused on advancing medical technologies to treat TEV. The Katana thrombectomy system is positioned to redefine treatment standards for pulmonary embolism (PE) by enabling the more efficient removal of diverse clot types. This commitment reflects their mission to revolutionize TEV care and create a lasting impact on patients' lives globally. For those interested in learning more about Akura Medical and their products, further information can be found on their website at Akura Medical.

It's worth noting that the Katana system is currently for experimental use only and is not yet approved for sale in the United States or any other country.

About Shifamed, LLC

Founded by serial entrepreneur Amr Salahieh, Shifamed is a highly specialized medical innovation center aimed at developing solutions that expedite market entry, mitigate risks, enhance impact, and pave the way for a world where patients can lead longer, healthier lives. To find out more about Shifamed, visit Shifamed.